Gene · 3362
HTR6: 5-hydroxytryptamine receptor 6
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HTR6: 5-hydroxytryptamine receptor 6. Genes, record 3362. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3362
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P50406 | 5-hydroxytryptamine receptor 6 | 440 | 3 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 35789 | P50406 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2015 | P50406 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2015 | P50406 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 434 | P50406 | Espacenet |
| JP 2023153821 A | 2023-10-18 | 38 | P50406 | Espacenet |
| JP 2023515708 A | 2023-04-13 | 17 | P50406 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 434 | P50406 | Espacenet |
| US 11407837 B2 | 2022-08-09 | 38 | P50406 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 304 | P50406 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 103405 | P50406 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs10
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| AMISULPRIDE | CHEMBL243712 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
| CERLAPIRDINE | CHEMBL2103880 | Serotonin 6 (5-HT6) receptor antagonist | ANTAGONIST | ChEMBL |
| DEXFENFLURAMINE | CHEMBL248702 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| DEXFENFLURAMINE HYDROCHLORIDE | CHEMBL1887891 | Serotonin (5-HT) receptor agonist | AGONIST | ChEMBL |
| IDALOPIRDINE | CHEMBL3286580 | Serotonin 6 (5-HT6) receptor antagonist | ANTAGONIST | ChEMBL |
| INTEPIRDINE | CHEMBL1083390 | Serotonin 6 (5-HT6) receptor antagonist | ANTAGONIST | ChEMBL |
| MASUPIRDINE | CHEMBL4117187 | Serotonin 6 (5-HT6) receptor antagonist | ANTAGONIST | ChEMBL |
| PF-05212377 | CHEMBL3329435 | Serotonin 6 (5-HT6) receptor antagonist | ANTAGONIST | ChEMBL |
| ZIMELDINE | CHEMBL37744 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
| ZIMELDINE HYDROCHLORIDE | CHEMBL2355333 | Serotonin (5-HT) receptor antagonist | ANTAGONIST | ChEMBL |
Trials62
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07152184 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06887621 | AMISULPRIDE | PHASE2 | ClinicalTrials.gov | |
| NCT06585540 | AMISULPRIDE | PHASE3 | ClinicalTrials.gov | |
| NCT06581302 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT06040944 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05956600 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT05397639 | MASUPIRDINE | PHASE3 | ClinicalTrials.gov | |
| NCT05347199 | AMISULPRIDE | PHASE1 | ClinicalTrials.gov | |
| NCT04954365 | AMISULPRIDE | ClinicalTrials.gov | ||
| NCT04533724 | AMISULPRIDE | EARLY_PHASE1 | ClinicalTrials.gov |
1 to 10 of 62
See all 62 trialsNIH grants697
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HTR6 papers | Newest fiscal year |
|---|---|---|---|
| P20GM109025 | Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission | 7 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 5 | 2025 |
| ZIAMH002793 | PET Radiopharmaceutical Sciences | 5 | 2025 |
| ZIAMH002795 | Translational Evaluation of PET Radiotracers | 3 | 2025 |
| P30AI050409 | Center for AIDS Research at Emory University | 2 | 2025 |
| P30DK020579 | Diabetes Research Center | 2 | 2025 |
| P30ES019776 | HERCULES: Exposome Research Center | 2 | 2025 |
| R01DA038446 | 5-HT2 Receptor Allosterism in Cocaine Use Disorder | 2 | 2025 |
| R01EB026299 | BrainStorm: Highly Extensible Software for Advanced Electrophysiology and MEG/EEG Imaging | 2 | 2025 |
| T32DA007287 | Translational Explorations in Substance Use Disorders | 2 | 2025 |
1 to 10 of 697Source NIH's project files
See all 697 nih grantsPapers1,299
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Multi-molecular adaptations of long-term opioid use in chronic pain. | Brain | 2026 | 42817590 | PubTator, text mining | PubMed |
| Comparative analysis of striatal subregions in behavioral variant frontotemporal dementia and late-life schizophrenia: A multimodal MRI study. | Int Psychogeriatr | 2026 | 42722600 | PubTator, text mining | PubMed |
| Multitarget interactions of bisphenol A in polycystic ovary syndrome: evidence from integrated network toxicology, mendelian randomization, and molecular docking. | F S Sci | 2026 | 42386029 | PubTator, text mining | PubMed |
| Association of Polymorphisms in Genes Involved in Serotonergic Signaling with the Risk of Developing Alzheimer's Disease. | Curr Alzheimer Res | 2026 | 42316566 | PubTator, text mining | PubMed |
| Primary cilia and neural computation. | J Biomed Sci | 2026 | 42231312 | PubTator, text mining | PubMed |
| Benzazepines Derivatives: Synthetic Strategy, Structural-Activity Relationships, and Medical Potential as Dopamine and Serotonin Receptor Modulators. | ACS Omega | 2026 | 42179638 | PubTator, text mining | PubMed |
| New chalcogen-optimized 1,3,5-triazines as dual 5-HT6R/FAAH modulators: A versatile approach to neurodegenerative disorders. | Eur J Med Chem | 2026 | 42166820 | PubTator, text mining | PubMed |
| Serotonergic Regulation of Nicotine Addiction: Receptor-specific Mechanisms and Therapeutic Strategies. | Curr Neurovasc Res | 2026 | 42099156 | PubTator, text mining | PubMed |
| Dually Acting Ligands Targeting Serotonin Receptors: Implications in CNS Disorders. | J Med Chem | 2026 | 42044264 | PubTator, text mining | PubMed |
| Receptor subtype distribution from PET occupancy studies: Novel analysis of maximum occupancy images using a selective drug and a non-selective tracer. | J Cereb Blood Flow Metab | 2026 | 41944349 | PubTator, text mining | PubMed |
1 to 10 of 1,299
See all 1,299 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3362
GET https://conductscience.org/api/genes/v1/3362/patents?page=2